Alkem Laboratories Ltd (ALKEM)
₹5,162.00
Mkt cap
₹62,658 Cr
P/E ratio
27.60
P/B
4.47
Div yield
1.01%
ROE
18.90%
ROCE
21.20%
EPS (TTM)
₹187.03
Book value
₹1,156
52W range
5,145–5,890
Sector
Healthcare
Price history
Previous close
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
NSE ALKEMBSE 539523
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−12.36% from high₹5,162
₹5,145+0.34% from low₹5,890
Current
₹5,162.00
Prev close
₹5,242.50
Day
−1.54%
Price performance
1D
−1.54%
1W
−2.60%
1M
−7.80%
3M
−2.59%
6M
−6.99%
1Y
−1.61%
YTD
−7.70%
Financials
Revenue, profit & margin
P/E ratio
27.6×
ALKEM is 22% below the sector median of 35.2×
ALKEM27.6×
Sector median35.2×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,968 | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 | |
| Expenses | 2,579 | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 | 2,974 | |
| Operating Profit | 389 | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 | |
| OPM % | 13% | 22% | 21% | 14% | 20% | 22% | 23% | 12% | 22% | 23% | 22% | 14% | 20% | |
| Other Income | 66 | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 | |
| Interest | 30 | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 | |
| Depreciation | 72 | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 | |
| Profit before tax | 353 | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 | |
| Tax % | 18% | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% | |
| Net Profit | 288 | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 | |
| EPS in Rs | 23.98 | 51.90 | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 | 25.58 | 55.56 | 63.99 | 53.19 | 19.78 | 43.49 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.53% · closed higher next day 17 of last 42
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25† | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 7 Nov '23◦ | 9 Feb '24◦ | 29 May '24◦ | 9 Aug '24◦ | 13 Nov '24◦ | 7 Feb '25◦ | 29 May '25 | 12 Aug '25 | 13 Nov '25 | 13 Feb '26 | 28 May '26◦ | 14 Aug '26◦ |
| Earnings day | +5.10% | −3.35% | −6.00% | −1.41% | −0.83% | −6.80% | −3.70% | +6.29% | −0.73% | −7.97% | +0.85% | +0.11% |
| +1 day | +6.34% | −0.65% | −8.59% | −1.51% | −1.01% | −8.69% | −3.74% | +11.23% | −0.78% | −6.64% | −2.51% | +1.99% |
| +5 days | +8.29% | +2.70% | −7.75% | −1.10% | −1.67% | −6.93% | −8.16% | +11.32% | −1.17% | −8.15% | −3.67% | −0.34% |
| +15 days | +15.41% | −3.81% | −2.53% | +5.38% | −1.55% | −10.42% | −9.84% | +9.43% | −1.88% | −6.99% | −1.43% | −2.34% |
| +30 days | +22.03% | −6.08% | −1.21% | +4.31% | +1.13% | −2.88% | −9.21% | +13.70% | −4.03% | −10.66% | +2.12% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202649.70%Promoter
Promoters49.70%1.50
FIIs10.42%0.27
DIIs22.64%1.25
Public17.25%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| ALKEM | ₹5,242.50 | 27.57 | 62,658 | 1.01% | 521 | −20.47% | 3,740 | +10.95% | 21.24% |
| Median: 158 Co. | ₹426.15 | 35.20 | 2,303 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024webAnnual Report 2024bseAnnual Report 2023webAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts90
TranscriptAug 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026PPTFeb 2026TranscriptFeb 2026PPTFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025PPTMar 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024PPTSep 2024TranscriptAug 2024
Credit ratings6
Announcements5
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 27 Aug - Alkem Laboratories’ 52nd AGM approved all resolutions, including final dividend and director reappointments, on 27 August 2026.Shareholder Meeting / Postal Ballot-Outcome of AGM 27 Aug - 52nd AGM held on 27 Aug 2026; all resolutions passed, including dividend and director reappointments.Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 26 AugAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript 20 Aug - Please find attached herewith Q1 FY27- Earnings Call Transcript.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 20 Aug - Please find attached herewith Q1 FY27- Earnings Call Transcript.